Showing results (1061-1070 of 3,104) with videos related to
Sort By:
Pageof 311
Drug Safety|February 23, 2021
Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug EventsSonam N Shah, Roseann S Gammal, Mary G Amato, et al.Drug Safety|February 12, 2021
Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES StudyAbdelkrim Ziad, Claudine Berr, Fabrice Ruiz, et al.Drug Safety|September 26, 2019
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic ReviewsEmanuel Raschi, Matteo Bianchin, Milo Gatti, et al.Drug Safety|October 21, 2018
Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular DevelopmentNadezda Abramova, Julie Hubbard, Joan Schertz, et al.Drug Safety|March 5, 2019
Established and Emerging Immunological Complications of Biological Therapeutics in Multiple SclerosisBabak Soleimani, Katy Murray, David HuntDrug Safety|March 14, 2019
Correction to: vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality IssuesTomas Bergvall, G Niklas Norén, Marie LindquistDrug Safety|December 21, 2021
Patient Safety Incidents Related to the Use of Parenteral Nutrition in All Patient Groups: A Systematic Scoping ReviewPriya Mistry, Rebecca Heather Smith, Andy FoxDrug Safety|December 20, 2021
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and ManageabilityErnest Nadal, Hidehito Horinouchi, Jin-Yuan Shih, et al.Drug Safety|March 15, 2014
Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibitionMinjie Lin, Shuiping Zhao, Li Shen, et al.Drug Safety|March 5, 2021
Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-AnalysisJuan S Lasa, Pablo A Olivera, Stefanos Bonovas, et al.Pageof 311